CN108024959A - 用于治疗乳腺病症的经乳头方法和组合物 - Google Patents

用于治疗乳腺病症的经乳头方法和组合物 Download PDF

Info

Publication number
CN108024959A
CN108024959A CN201680052914.XA CN201680052914A CN108024959A CN 108024959 A CN108024959 A CN 108024959A CN 201680052914 A CN201680052914 A CN 201680052914A CN 108024959 A CN108024959 A CN 108024959A
Authority
CN
China
Prior art keywords
composition
breast
vitamin
carcinoma
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680052914.XA
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·C·夸伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Genetics Inc filed Critical Atossa Genetics Inc
Publication of CN108024959A publication Critical patent/CN108024959A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680052914.XA 2015-07-14 2016-07-14 用于治疗乳腺病症的经乳头方法和组合物 Pending CN108024959A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192505P 2015-07-14 2015-07-14
US62/192,505 2015-07-14
PCT/US2016/042202 WO2017011623A1 (en) 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders

Publications (1)

Publication Number Publication Date
CN108024959A true CN108024959A (zh) 2018-05-11

Family

ID=57757662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680052914.XA Pending CN108024959A (zh) 2015-07-14 2016-07-14 用于治疗乳腺病症的经乳头方法和组合物

Country Status (7)

Country Link
US (1) US20180200206A1 (cg-RX-API-DMAC7.html)
EP (1) EP3322406A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018520182A (cg-RX-API-DMAC7.html)
CN (1) CN108024959A (cg-RX-API-DMAC7.html)
AU (1) AU2016294526A1 (cg-RX-API-DMAC7.html)
CA (1) CA2992282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017011623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
EP3679061A4 (en) * 2017-09-06 2021-06-09 University of Cincinnati METHOD OF PREDICTING BREAST LESIONS IN EARLY STAGE
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
CN110221068B (zh) * 2018-03-02 2020-09-18 中国医学科学院基础医学研究所 检测Kyn含量的试剂的应用
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040030248A1 (en) * 2002-03-19 2004-02-12 Cytyc Health Corporation Intraductal management of breast lesions involving therapeutic or diagnostic agents
US20040092894A1 (en) * 1999-03-01 2004-05-13 Cytyc Health Corporation Apparatus, methods and kits for simulaneous delivery of a substance to multiple breast milk ducts
US20040208830A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
CN1917910A (zh) * 2003-12-23 2007-02-21 Cytyc公司 用于进入乳腺管以执行医疗程序的医疗器械及其方法
US20100112041A1 (en) * 2006-11-21 2010-05-06 Jina Pharmaceuticals, Inc. Endoxifen Compositions And Methods
US20120010245A1 (en) * 2008-12-11 2012-01-12 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising a serm
US20140088059A1 (en) * 2012-07-13 2014-03-27 South Dakota State University Compositions and Methods for Localized Drug Delivery through Mammary Papillae
CN104203961A (zh) * 2012-03-05 2014-12-10 泽维尔大学 作为用于乳腺癌的治疗的基于硼的4-羟基他莫昔芬和因多昔芬前药
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US20020117169A1 (en) * 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
JP2004530659A (ja) * 2001-02-28 2004-10-07 ジャイルズ,ブライアン,シー. 抗腫瘍および抗転移作用のための方法および処方
KR100419298B1 (ko) * 2003-07-28 2004-02-18 조규학 부착형 브래지어 및 그 제조방법
US20050142315A1 (en) * 2003-12-24 2005-06-30 Desimone Joseph M. Liquid perfluoropolymers and medical applications incorporating same
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
WO2007067773A2 (en) * 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2009105640A1 (en) * 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
WO2009129352A2 (en) * 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases
US9517183B2 (en) * 2012-01-30 2016-12-13 Patrick B. Ward Nipple abrasion protector
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092894A1 (en) * 1999-03-01 2004-05-13 Cytyc Health Corporation Apparatus, methods and kits for simulaneous delivery of a substance to multiple breast milk ducts
US20040030248A1 (en) * 2002-03-19 2004-02-12 Cytyc Health Corporation Intraductal management of breast lesions involving therapeutic or diagnostic agents
US20040208830A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
CN1917910A (zh) * 2003-12-23 2007-02-21 Cytyc公司 用于进入乳腺管以执行医疗程序的医疗器械及其方法
US20100112041A1 (en) * 2006-11-21 2010-05-06 Jina Pharmaceuticals, Inc. Endoxifen Compositions And Methods
US20120010245A1 (en) * 2008-12-11 2012-01-12 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising a serm
CN104203961A (zh) * 2012-03-05 2014-12-10 泽维尔大学 作为用于乳腺癌的治疗的基于硼的4-羟基他莫昔芬和因多昔芬前药
US20140088059A1 (en) * 2012-07-13 2014-03-27 South Dakota State University Compositions and Methods for Localized Drug Delivery through Mammary Papillae
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAUSHALKUMAR DAVE ET AL.: "Transpapillary Drug Delivery to the Breast", 《PLOS ONE》 *
LAY MING LEE ET AL.: "In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple)", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *
MARTIN C.DYCK ET AL: "The anticancer effects of Vitamin D and omega-3 PUFAs in combination via cod-liver oil: One plus one may equal more than two", 《MED HYPOTHESES》 *

Also Published As

Publication number Publication date
AU2016294526A1 (en) 2018-02-08
JP2018520182A (ja) 2018-07-26
EP3322406A1 (en) 2018-05-23
WO2017011623A1 (en) 2017-01-19
CA2992282A1 (en) 2017-01-19
US20180200206A1 (en) 2018-07-19
EP3322406A4 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
Rizzoli et al. Cancer-associated bone disease
ES2991315T3 (es) Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata
Paridaens et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
EP3797770B1 (en) Softgel capsule comprising apalutamide
JP2018520182A (ja) 乳房障害を処置するための経乳頭方法及び組成物
Brown et al. Denosumab in patients with cancer—a surgical strike against the osteoclast
Love et al. A feasibility study of the intraductal administration of chemotherapy
Kataja et al. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
WO2000043038A1 (en) Methods and devices for delivery of agents to breast milk ducts
Dixon et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
KR20200103764A (ko) 유방 장애의 관내 치료 방법
US20260041695A1 (en) Combination therapies for treatment of breast cancer
Boers et al. Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer
US20160375234A1 (en) Transpapillary methods and compositions for diagnosing and treating breast conditions
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
Strube et al. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption
TW201600086A (zh) 用於治療三陰性乳癌之維利帕尼(veliparib)與卡鉑之組合
Wang et al. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR
HK1255302A1 (en) Transpapillary methods and compositions for treating breast disorders
WO2015166355A2 (en) Targeted therapy to restore radioactive iodine transport in thyroid cancer
Reddy et al. Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer
Mucha et al. Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years’ observation
Biswas Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
JP2025535957A (ja) がんの特定および/または治療
Nicolini et al. Final Results of a 2: 1 Control Case Observational Study with Interferon Beta and Interleukin-2 in Addition to First-Line Hormone Therapy in ER+ Endocrine Responsive Metastatic Breast Cancer Patients.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255302

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Washington State

Applicant after: Atosa therapeutics

Address before: Washington State

Applicant before: ATOSSA GENETICS, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180511

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1255302

Country of ref document: HK